AstraZeneca will work with Mexico, Argentina to produce COVID-19 vaccine doses

Syringe injection vaccine needle
AstraZeneca has been on a run of national supply deals for its COVID-19 shot. (Pixabay)

AstraZeneca's gung-ho effort to lock in national supply deals for its COVID-19 vaccine candidate has paid off in recent weeks with a series of expensive agreements. Now, the British drugmaker will work with Mexico and Argentina to pump up supply to Latin American countries. 

The two countries will produce between 150 million and 250 million doses of AstraZeneca and the University of Oxford's adenovirus-based vaccine at no profit starting in the first half of 2021.

The local production pacts are contingent on successful clinical trials, and Argentina's health minister told Bloomberg the country would target the elderly, patients with pre-existing conditions, and front-line health care workers with the first doses. 

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

Mexico's effort, funded in part by billionaire business magnate Carlos Slim, comes as the country has emerged as one of the leading COVID-19 hotspots with nearly half a billion cases since the pandemic's start, according to the Johns Hopkins Coronavirus Resource Center. Argentina, meanwhile, has reported around 268,000 cases so far. 

The newest deal continues AstraZeneca's run of national supply pacts, designed to piece together the 2 billion doses the company aims to deliver each year. 

RELATED: AstraZeneca bumps up vaccine deal with Brazil to $360M with more doses, licensing rights

Last week, the drugmaker and the Brazilian government announced plans to ramp up an earlier supply deal, with Brazil pledging $360 million to the effort. 

Those funds will cover an initial 100 million-dose order, AstraZeneca said, as well as Brazil's licensing rights to produce the shot at the Oswaldo Cruz Foundation, also known as Fiocruz, if the vaccine is found effective in clinical trials.

An AstraZeneca spokesman said the new agreement "builds on" the drugmaker's earlier deal with Brazil in June to supply around 30 million unfinished doses of the vaccine at a price tag of $127 million, or around $4 per dose.

RELATED: AstraZeneca taps JCR Pharmaceuticals, Daiichi Sankyo and other local pharmas to supply COVID-19 shots to Japan

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.